Treatment for up to three years with Onapgo (apomorphine hydrochloride) — approved in the U.S. earlier this year as an add-on therapy for advanced Parkinson’s disease — significantly and sustainably reduced off time, when symptoms are not fully controlled, in adults with the neurodegenerative condition. Importantly, the researchers…
Although physical exercise has well-established benefits for people with Parkinson’s disease, too much of it may worsen fatigue and motor symptoms, according to a report of two cases in the U.K. Both patients believed that intense exercise could help them overcome the disease, including reversing the degeneration of dopaminergic…
Vyalev (foscarbidopa and foslevodopa) demonstrated a favorable long-term safety and tolerability profile, along with sustained motor symptom control, in Parkinson’s disease patients who participated in the extension part of a Phase 3 trial (NCT03781167). Results from nearly two years of the extension study (NCT04379050) showed…
Nitrase Therapeutics’ NDC-0524, an antibody therapy for Parkinson’s disease, significantly reduced alpha-synuclein aggregation and spreading in mouse models of the disease, according to preclinical data released by the company. The antibody targets nitrated alpha-synuclein, a misfolded form of the protein that forms toxic clumps in dopaminergic neurons, the nerve cells…
A new collaborative effort between Mayo Clinical Laboratories and Amprion will expand access to the diagnostic company’s SAAmplify–αSYN test — designed to detect the presence of abnormal alpha-synuclein protein in people suspected of having neurodegenerative diseases — across the U.S., according to a joint press release.
Researchers at the University of Delaware have developed a model that combines artificial intelligence with magnetic resonance elastography (MRE) to measure brain stiffness and volume for predicting brain age. MRE is a noninvasive method that can measure changes in brain stiffness by using a gentle vibration of a person’s head…
Newronika is preparing for the commercial launch of AlphaDBS — a next-generation adaptive deep brain stimulation (DBS) system for treating Parkinson’s disease — at selected markets in Europe this year, following CE Mark approval in the European Union. That’s according to a company press release, in which…
Neuropacs‘ MRI-based artificial intelligence (AI) technology demonstrated 96% accuracy in distinguishing Parkinson’s disease from atypical parkinsonism — including multiple system atrophy, known as MSA, and progressive supranuclear palsy, called PSP — the company announced, detailing the results of a federally funded U.S. study. Moreover, the system achieved 98%…
Parkinson Italia — a network of 30 associations for patients and caregivers in Italy — is backing an initiative by the Prada Foundation that seeks to highlight the importance of prevention and early treatment of neurodegenerative diseases like Parkinson’s. The campaign, dubbed Preserving the Brain: A…
Most people with early-stage Parkinson’s disease have sleep disturbances, with many having more than one at the same time, a study in France suggests. Sleep disorders were mainly associated with body changes, including motor symptoms and problems regulating involuntary bodily functions, rather than depression or anxiety. “The timely…
Get regular updates to your inbox.
